Nucleoside and nucleotide analogs to inhibit the viral RNA polymerase
Also Clin2 hepatitis C; AT-752 Clin2 Dengue; undisclosed programs Clin0 COVID-19
Atea Pharmaceuticals is developing oral direct-acting antiviral therapies. Single-stranded positive-sense RNA viruses, such as SARS-CoV-2, account for a large number of clinically serious global pathogens. To multiply in number, these viruses depend on an enzyme called RNA-dependent RNA polymerase. Atea is identifying oral inhibitors of this enzyme through the use of their purine nucleotide prodrug platform. The platform screens a large library of nucleoside and nucleotide analogs prodrugs that are uniquely active against RNA viruses.- Using their experience of developing antivirals, Atea is then enhancing the antiviral activity and selectivity through specific chemical modifications. Atea’s lead product candidate, AT-527, is being developed as a monotherapy for COVID-19.